Idorsia Ltd

IDRS.SW

SIXBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
Lucerastat	Phase 3	Fabry Disease	-
Daridorexant 10 mg	Phase 3	Insomnia Disorder	-
tezosentan	Phase 3	Acute Heart Failure	-
Daridorexant 50 mg	Phase 3	Insomnia Disorder	-
Daridorexant	Phase 3	Insomnia Disorder	-
Cetirizine	Phase 3	Seasonal Allergic Rhinitis	-
Aprocitentan 12.5 mg	Phase 3	Resistant Hypertension	-
ACT-539313	Phase 2	Binge-Eating Disorder	-
Zolpidem	Phase 2	Insomnia Disorder	-
ACT-129968	Phase 2	Seasonal Allergic Rhinitis	-
ACT-709478 for oral use	Phase 2	Photosensitive Epilepsy	-
Aprocitentan 5 mg	Phase 2	Essential Hypertension	-
Clazosentan 1 mg/h	Phase 2	Aneurysmal Subarachnoid Hemorrhage	-
ACT-541468	Phase 2	Insomnia Disorder	-
ACT-774312	Phase 2	Bilateral Nasal Polyposis	-
Daridorexant 25 mg	Phase 2	Insomnia	-
Clazosentan	Phase 2	Aneurysmal Subarachnoid Hemorrhage	-
ACT-541468 5 mg	Phase 2	Insomnia Disorder	-
ACT-280778	Phase 2	Essential Hypertension	-
Placebo	Phase 2	Asthma	-

Catalyst Timeline

2 upcoming, 0 past

Phase 2Next

March 2026~Daridorexant 25 mg

Primary completion for Daridorexant 25 mg trial (NCT05423717) in Insomnia

Phase 2

March 2026~Daridorexant 10 mg

Primary completion for Daridorexant 10 mg trial (NCT05423717) in Insomnia

Regulatory Approvals

IDRS.SW News